ACADIA Pharmaceuticals, Inc.

Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing over 20 years of pharmaceutical industry experience.

The U.S. District Court for the District of Delaware ruled in favor of Acadia Pharmaceuticals, upholding their '721 formulation patent for Nuplazid against Aurobindo Pharma's generic challenge.

A U.S. District Court ruled that Aurobindo Pharma infringes on two key patent claims held by Acadia Pharmaceuticals for its Parkinson's disease drug Nuplazid.

The FDA has approved trofinetide (developed by ACADIA Pharmaceuticals) as the first-ever treatment for Rett syndrome, a rare genetic disorder primarily affecting females that causes severe developmental delays and neurological symptoms.

Priority Review Vouchers (PRVs) have surged in value to $150-158 million in recent months, up from the typical $100 million, following Congress's failure to reauthorize the rare pediatric disease program.

Acadia Pharmaceuticals and Saniona successfully completed Phase 1 multiple-ascending-dose study of ACP-711 in healthy volunteers, demonstrating favorable safety and tolerability profile.

Caregivers reported marked improvements in communication abilities, including new sounds and words, and enhanced eye contact in Rett syndrome patients treated with Daybue in clinical trials.

Acadia Pharmaceuticals has submitted a Marketing Authorization Application (MAA) to the EMA for trofinetide to treat Rett syndrome in adults and children.

Acadia Pharmaceuticals anticipates exceeding $1 billion in net sales in 2025, driven by strong performance from NUPLAZID and DAYBUE.

A recent survey presented at the American Epilepsy Society (AES) 2024 Annual Meeting indicates that titrating trofinetide improves tolerability in treatment-naive Rett syndrome patients.